- Home
- VRCA vs PLUR Comparison
VRCA vs PLUR Comparison
Compare VRCA & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | PLUR |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 34.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRCA | PLUR |
|---|---|---|
| Price | $8.28 | $3.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 402.7K | 47.8K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,829,000.00 | $1,326,000.00 |
| Revenue This Year | $373.65 | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | 121.74 |
| 52 Week Low | $3.28 | $3.02 |
| 52 Week High | $9.82 | $7.13 |
Technical Indicators
Market Signals| Indicator | VRCA | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 63.22 | 37.37 |
| Support Level | $7.82 | $3.10 |
| Resistance Level | $9.78 | $3.92 |
| Average True Range (ATR) | 1.17 | 0.31 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 65.21 | 11.32 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.